26 January 2018
- アストラゼネカが慢性気道閉塞症（COPD)治療薬として開発中の３成分合剤PT010のフェーズIIIクロノス（KRONOS）試験成績を報告。
PT010 demonstrates significant improvement in six out of seven lung function primary endpoints compared with dual combination therapies
AstraZeneca today announced top-line results from the Phase III KRONOS trial that showed PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6µg, using Aerosphere Delivery Technology, in a pressurised metered-dose inhaler or pMDI) demonstrated a statistically significant improvement compared with dual combination therapies in six out of seven lung function primary endpoints based on forced expiratory volume in one second (FEV1) assessments in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). In total, eight of the nine primary endpoints in the KRONOS trial were met, including two non-inferiority endpoints to qualify PT009, one of the comparators.
